News / Taiwan / economic_daily
Ennoconn Subsidiary AJ Bio Files for Phase III Clinical Trial of SBMA Drug
Health Technology · Biotechnology · economic_daily · 2026-09-03
7754
AJ Bio has submitted an IND application to the US FDA for its SBMA treatment, AJ201, aiming to leverage orphan drug status for global licensing deals.
What Happened
Advancing to Phase III: AJ Bio has officially submitted an Investigational New Drug (IND) application to the US FDA for its Phase III clinical trial of AJ201, a treatment for Spinal and Bulbar Muscular Atrophy (SBMA). The trial plans to enroll approximately 200 patients globally, with the timeline subject to adjustments by international licensing partners.
Development Advantages: AJ201 has been granted orphan drug designation by both the US FDA and the European EMA, along with FDA fast-track status. The drug is protected by patents in 19 countries, with potential patent protection extending until 2044 upon approval of its new pharmaceutical composition patent.
Significant Market Potential: Market research indicates that there are over 12,000 diagnosed SBMA patients worldwide, with the potential annual market size reaching US$2.5 billion. This Phase III filing significantly strengthens AJ Bio's position and leverage in ongoing international licensing negotiations.
Accelerating Global Strategy: Chairwoman Huang Wen-ying stated that this filing marks a critical milestone in the company's drug development journey. AJ Bio remains committed to advancing global patent licensing and strategic partnerships to accelerate the development and eventual commercialization of AJ201.